Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.02

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $5.02.

A number of analysts recently weighed in on CTMX shares. StockNews.com cut shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday. HC Wainwright reissued a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $5.00 target price on shares of CytomX Therapeutics in a research report on Friday, March 7th.

CytomX Therapeutics Stock Down 8.8 %

Shares of CTMX stock opened at $0.58 on Friday. The stock has a 50-day simple moving average of $0.73 and a 200 day simple moving average of $0.95. The stock has a market capitalization of $46.46 million, a P/E ratio of 3.41 and a beta of 1.05. CytomX Therapeutics has a fifty-two week low of $0.56 and a fifty-two week high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.45. The company had revenue of $38.09 million during the quarter, compared to the consensus estimate of $13.53 million. CytomX Therapeutics had a net margin of 10.96% and a negative return on equity of 41.47%. On average, sell-side analysts anticipate that CytomX Therapeutics will post -0.05 earnings per share for the current year.

Institutional Trading of CytomX Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Miller Financial Services LLC acquired a new stake in shares of CytomX Therapeutics in the fourth quarter worth $26,000. Traphagen Investment Advisors LLC acquired a new stake in CytomX Therapeutics during the 4th quarter worth about $31,000. Algert Global LLC purchased a new position in CytomX Therapeutics during the 4th quarter valued at about $35,000. Velan Capital Investment Management LP purchased a new position in CytomX Therapeutics during the 4th quarter valued at about $36,000. Finally, Aspire Growth Partners LLC acquired a new position in shares of CytomX Therapeutics in the 4th quarter valued at about $42,000. 67.77% of the stock is owned by institutional investors and hedge funds.

About CytomX Therapeutics

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.